Harmony Biosciences announced a planned leadership transition where President and CEO Jeffrey M. Dayno, M.D., will retire at the end of the year. The Board has appointed current Chief Operating Officer, Peter Anastasiou, to succeed him. In conjunction with the announcement, the company reiterated its full-year 2026 revenue guidance.
Key Details
- Outgoing CEO: Jeffrey M. Dayno, M.D., will retire as President & CEO and step down from the Board, effective December 31, 2026. He will continue as a non-executive advisor through 2027.
- Incoming CEO: Peter Anastasiou, the current COO, will be appointed President, CEO, and a member of the Board, effective January 1, 2027.
- Guidance Reaffirmed: The company reiterated its full-year 2026 WAKIX® net revenue guidance of $1.0 billion to $1.04 billion.